摘要
[目的]探讨鼻咽癌患者治疗过程中T细胞亚群、CD34检测的临床意义。[方法]应用流式细胞仪测定67例鼻咽癌患者治疗前、治疗4周以及治疗后1个月T细胞亚群、CD34和常规检查血液学情况,20例健康人群为对照组。[结果]血液学常规显示鼻咽癌患者白细胞、血红蛋白、血小板以及尿酸在治疗过程中与对照组比较均无显著性差异(P>0.05)。治疗前CD8+和CD4+/CD8+显著性低于正常组(P<0.05)。患者放疗和同期放化疗期间CD34明显下降,CD3+、CD4+、CD8+、CD4+/CD8+升高。鼻咽癌组治疗后1个月CD8+、CD4+/CD8+显著性高于对照组(P<0.05)。鼻咽癌同期放化疗患者CD34治疗4周和治疗后1个月均显著低于单纯放疗组(P<0.05),且治疗后1个月CD3+、CD4+显著高于单纯放疗组(P<0.05)。[结论]T细胞亚群变化可评估鼻咽癌患者治疗过程中的免疫功能状态,CD34可用于观察放化疗对骨髓功能影响。
[Purpose] To investigate the clinical value of detecting T cell subsets and CD34 during treatment in patients with nasopharyngeal carcinoma（NPC）. [Methods ] T cell subsets and CD34 of 67 cases with NPC before treatment, were enrolled 4 weeks and 1 month after treatment were de- tected by flow cytometry. Twenty healthies as controls. [ Results ] Routine blood test showed that the level of leucocyte, hemoglobin, bloodplatelet and uric acid had no significant difference be- tween NPC group and healthy control group （P〉0.05）. CD8＋ and CD4＋/CD8＋ in NPC group were significantly higher than those in healthy control group before treatment （P〈0.05）. CD34 declined sharply during radiotherapy or concurrent radio chemotherapy, but CD3＋ and CD4＋, CD8＋, CD4＋/CD8＋ were elevated. CD8＋ and CD4＋/CD8＋ in NPC group were significantly higher than those in healthy control group at one month after treatment （P〈0.05）.CD34 in NPC with concurrent radiochemotherapy group was significantly lower than in that NPC with radiotherapy at 4 weeks and one month after treatment （P〈O.OS）.But CD3＋ and CD4＋ in concurrent radioehemotherapy group were significantly lower than those in radiotherapy group at one month after treatment （P〈 0.05）. [Conclusion] The changes of T cell subsets are useful for evaluating the status of immunity in NPC. CD34 can be used for surveillance of the impact of radiotherapy and chemotherapy on the bone marrow.
出处
《肿瘤学杂志》
CAS
2012年第1期37-39,共3页
Journal of Chinese Oncology
